Abnormal Involuntary Movement Scale - Scoring (AIMSDVD.com)
The Abnormal Involuntary Movement Scale (AIMSDVD. com)Training DVD is a unique resource for educators.
Yahoo answers: My daughter is 15 has adhd and is taking lexapro,vyvance,geodom has been a month and?
She attitude change, she is aggressive, i noticed her mouth twitching,her grades went down, sleeps a lot thing that she never did, arguing for everything, has me in the edge of a nervous break down. crying a lot, her legs she said that is...04/04/12
Okay first and foremost who is the physician presribing these medications for your daughter anyway? Is he a child psychiatrist or family physician? Either way here is the deal with your daughter...
Latest news about extrapyramidal disease and abnormal movement disorder
Depression, Anxiety Common in New PD Patients
Neuropsychiatric symptoms are common in newly diagnosed, untreated patients with Parkinson's disease (PD), but they remain relatively stable over a 2-year follow-up, initial longitudinal data show. Patricia de la Riva, MD, University Hospital Donostia
Intra-Cellular Therapies Announces Topline Safety Results From Phase I/II ...
NEW YORK, Oct. 13, 2014 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced topline results from ITI-007
Cerebral palsy (CP) is a group of neurological disorders caused by a non-progressive brain injury or malformation that occurs while a child's brain is developing. The symptoms manifest in infancy or early childhood and permanently affect body movement
The World Health Organization's International Classification of Diseases (10th Edition, ICD-10) describes schizophrenia as a severe psychotic illness that is not attributable to alcohol or substances, or to organic brain disease. Tardive dyskinesia
Intra-Cellular Therapies Presents New Data From the Phase 2 Clinical Trial of ...
Intra-Cellular Therapies, Inc. ITCI, -0.53% a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders is presenting additional data from the Phase 2 clinical trial of ITI-007 in schizophrenia at